Kumar Sanjeev Srinivas, Pacey Simon
Department of Oncology, Addenbrookes Hospital, Cambridge, UK.
J Clin Urol. 2016 Dec;9(2 Suppl):30-37. doi: 10.1177/2051415816685211. Epub 2016 Dec 1.
While early treatment of primary prostate cancer is very effective, the incidence of primary prostate cancer continues to rise and therefore the detection of men with high-risk non-metastatic prostate cancer and their subsequent management is becoming increasingly important. There continues to be no molecularly-targeted or chemotherapeutic options with proven, statistically significant survival benefit in this setting. However, there are indications that further risk stratification using molecular features could potentially help distinguish indolent from aggressive prostate cancer, ultimately providing biological markers that could guide a more personalised approach to therapy selection.
虽然原发性前列腺癌的早期治疗非常有效，但原发性前列腺癌的发病率仍在持续上升，因此，检测高危非转移性前列腺癌男性患者并对其进行后续管理变得越来越重要。在这种情况下，仍然没有经证实具有统计学显著生存获益的分子靶向或化疗方案。然而，有迹象表明，利用分子特征进行进一步的风险分层可能有助于区分惰性前列腺癌和侵袭性前列腺癌，最终提供能够指导更个性化治疗选择方法的生物标志物。
